3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Cancer Metastatic
3
Neoplasm Metastasis
2
Uveal Melanoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neurofibromatosis 2
1
Neoplasms
1
Macular Degeneration
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Carcinoma
1
Interventions
Prednisone
53
Radiotherapy
52
Docetaxel
51
Leuprolide
48
Goserelin
47
bicalutamide
45
enzalutamide
28
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
27
Androgen Antagonists
27
Flutamide
24
Triptorelin Pamoate
22
apalutamide
18
Gonadotropin-Releasing Hormone
18
Abiraterone Acetate
17
Radiation
15
abiraterone
14
Zoledronic Acid
14
Magnetic Resonance Spectroscopy
13
gallium 68 PSMA-11
12
Prednisolone
11
luprolide acetate gel depot
10
darolutamide
9
Radiosurgery
9
cabazitaxel
8
Standard of Care
8
Specimen Handling
8
Radiotherapy, Intensity-Modulated
8
Radiotherapy, Conformal
8
Estramustine
8
Dexamethasone
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Prostatic Neoplasms
×
aflibercept
×
Clear all
NCT00519285
2016-07-22
VENICE
Sanofi
Phase 3
Completed
1,224 enrolled
21 charts